Nitric Oxide Synthesis Is Reduced in Subjects With Type 2 Diabetes and Nephropathy
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Nitric oxide (NO) is a key metabolic and vascular regulator. Its production is stimulated by insulin. A reduced urinary excretion of NO products (NOx) is frequently found in type 2 diabetes, particularly in association with nephropathy. However, whether the decreased NOx excretion in type 2 diabetes is caused by a defective NOx production from arginine in response to hyperinsulinemia has never been studied. RESEARCH DESIGN AND METHODS: We measured NOx fractional (FSR) and absolute (ASR) synthesis rates in type 2 diabetic patients with diabetic nephropathy and in control subjects, after l-[15N2-guanidino]-arginine infusion, and use of precursor–product relationships. The study was conducted both before and after an euglycemic hyperinsulinemic (∼1,000–1,200 pmol/l) clamp. RESULTS: In type 2 diabetes, NOx FSR was reduced both under basal (19.3 ± 3.9% per day, vs. 22.9 ± 4.5% per day in control subjects) and hyperinsulinemic states (24.0 ± 5.6% per day, vs. 37.9 ± 6.4% per day in control subjects; P < 0.03 by ANOVA). Similarly, in type 2 diabetes, NOx ASR was lower than in control subjects under both conditions (basal, 0.32 ± 0.06 vs. 0.89 ± 0.34 mol per day; hyperinsulinemia, 0.35 ± 0.07 vs. 1.15 ± 0.38 mol per day; P = 0.01 by ANOVA). In type 2 diabetes, the ability of insulin to stimulate both the FSR (4.7 ± 3.2% per day) and the ASR (0.03 ± 0.04 mol per day) of NOx was several-fold lower than that in control subjects (15.0 ± 2.9% per day and 0.25 ± 0.07 mol per day, P < 0.03 and P < 0.02, respectively). Also the fraction of arginine flux converted to NOx (basal, 0.22 ± 0.05% vs. 0.65 ± 0.25%; hyperinsulinemia, 0.32 ± 0.06% vs. 1.03 ± 0.33%) was sharply reduced in the patients (P < 0.01 by ANOVA). CONCLUSIONS: In type 2 diabetic patients with nephropathy, intravascular NOx synthesis from arginine is decreased under both basal and hyperinsulinemic states. This defect extends the concept of insulin resistance to NO metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309 · cited 1×
“The glomerular filtration rate (GFR) in the diabetic subjects was determined by (51)Cr- EDTA infusion (21), and in both study groups it was estimated also using the CockcroftGault formula (22).”
Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids
Green, L. C., Wagner, D. A., Glogowski, J., Skipper, P. L., Wishnok, J. S., & Tannenbaum, S. R. (1982) · Analytical Biochemistry · doi:10.1016/0003-2697(82)90118-x · Cited by 12,077 · cited 1×
“tubes as nitrobenzene derivative (24), by Gas Chromatography CombustionIsotope Ratio Mass-Spectrometry (GC-CIRMS) (Delta Plus GC-C-IRMS, ThermoElectron, Bremen, Germany), as described in detail elsewhere (20).”
The L-Arginine-Nitric Oxide Pathway
Epstein, F. H., Moncada, S., & Higgs, A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292706 · Cited by 6,678
Regulation of biosynthesis of nitric oxide.
Nathan, C., & Xie, Q. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36703-0 · Cited by 1,669
The Role of Inflammatory Cytokines in Diabetic Nephropathy
Navarro-González, J. F., & Mora-Fernández, C. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007091048 · Cited by 932
Zeng, G., & Quon, M. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118871 · Cited by 726 · cited 2×
“In vascular endothelial cells, insulin stimulates NO production in a dosedependent fashion through the phosphatidylinositol 3 (PI-3)kinase/protein kinase B (Akt) pathway (29).”
Radioactive and Stable Isotope Tracers in Biomedicine: Principles and Practice of Kinetic Analysis
Wolfe, R. R. (1992) · Medical Entomology and Zoology · Cited by 610
Impaired Insulin-Mediated Skeletal Muscle Blood Flow in Patients With NIDDM
Laakso, M., Edelman, S. V., Brechtel, G., & Baron, A. D. (1992) · Diabetes · doi:10.2337/diab.41.9.1076 · Cited by 470 · cited 7×
“T2DM, type 2 diabetic subjects.”
InfluentialRadioactive and Stable Isotope Tracers in Biomedicine
Bramlet, R. (1993) · Clinical Nuclear Medicine · doi:10.1097/00003072-199305000-00027 · Cited by 395
Watkins, C. C., Sawa, A., Jaffrey, S., Blackshaw, S., Barrow, R. K., Snyder, S. H., & Ferris, C. D. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8273 · Cited by 268 · cited 7×
“T2DM, type 2 diabetic subjects.”
InfluentialNitrite and Nitrate Analyses: A Clinical Biochemistry Perspective
Ellis, G., Adatia, I., Yazdanpanah, M., & Makela, S. K. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00015-0 · Cited by 264 · cited 1×
“Blood NOx concentrations were determined from the ethanol supernatant (25), using a commercial assay (Nitrate/Nitrite Colorimetric Assay Kit, Cayman Chemical Co.”
Platelet-Endothelium Interactions
Flier, J. S., Underhill, L. H., Ware, J. A., & Heistad, D. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199303043280907 · Cited by 250
Radioimmunoassay for Urinary Albumin Using a Single Antibody
Miles, D. W., Mogensen, C. E., & Gundersen, H. J. G. (1970) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365517009049206 · Cited by 250
Arginine, arginine analogs and nitric oxide production in chronic kidney disease
Baylis, C. (2006) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0143 · Cited by 237 · cited 1×
“Urinary NOx production is reduced in non-diabetic renal disease (16), although also increased plasma nitrate concentrations have been reported in T2DM, as well as in the Metabolic”
Vincent, M. A., Montagnani, M., & Quon, M. J. (2003) · Current Diabetes Reports · doi:10.1007/s11892-003-0018-9 · Cited by 231 · cited 3×
“3 itric oxide is a key regulatory molecule with extensive metabolic, vascular and cellular effects (1-6).”
Kapur, S., Bédard, S., Marcotte, B., Côté, C. H., & Marette, A. (1997) · Diabetes · doi:10.2337/diab.46.11.1691 · Cited by 225
Renal Inulin Clearance versus Total Plasma Clearance of51Cr-EDTA
Bröchner-mortensen, J., Giese, J., & Rossing, N. (1969) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365516909081695 · Cited by 223
Stehouwer, C. D. A., Henry, R. M. A., Dekker, J. M., Nijpels, G., Heine, R. J., & Bouter, L. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.09211.x · Cited by 211 · cited 1×
“Conversely, microalbuminuria is associated with impaired endothelial function in T2DM subjects (14).”
Diabetic Nephropathy Is Associated with Oxidative Stress and Decreased Renal Nitric Oxide Production
Prabhakar, S., Starnes, J., Shi, S., Lonis, B., & Tran, R. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080895 · Cited by 203 · cited 1×
“A reduced urinary excretion of nitric oxide-related products, such as nitrites and nitrates, collectively termed as [NOx], has been reported in T2DM patients with nephropathy (12, 13).”
Insulin signaling in the arterial wall
Hsueh, W. A., & Law, R. E. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00353-7 · Cited by 200 · cited 1×
“Conversely, insulin resistance at this level impairs insulin-mediated vasodilation and results in endothelial dysfunction (29).”
BackgroundOn the mechanism and biology of cytochrome oxidase inhibition by nitric oxide
Antunes, F., Boveris, A., & Cadenas, E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405368101 · Cited by 189 · cited 1×
“3 itric oxide is a key regulatory molecule with extensive metabolic, vascular and cellular effects (1-6).”
Nitric oxide availability in diabetes mellitus
Honing, M. L. H., Morrison, P. J., Banga, J. D., Stroes, E. S. G., & Rabelink, T. J. (1998) · Diabetes / Metabolism Reviews · doi:10.1002/(sici)1099-0895(1998090)14:3<241::aid-dmr216>3.0.co;2-r · Cited by 189 · cited 7×
“T2DM, type 2 diabetic subjects.”
InfluentialInsulin action and insulin resistance in vascular endothelium
Muniyappa, R., & Quon, M. J. (2007) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32819f8ecd · Cited by 173 · cited 12×
“3 itric oxide is a key regulatory molecule with extensive metabolic, vascular and cellular effects (1-6).”
InfluentialWijekoon, E. P., Skinner, C., Brosnan, M. E., & Brosnan, J. T. (2004) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y04-067 · Cited by 153 · cited 1×
“Plasma taurine concentrations may be increased in insulin-resistant states (42).”
Essential Hypertension: An Insulin-Resistant State
Ferrannini, E., Haffner, S. M., & Stern, M. P. (1990) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199000005-00004 · Cited by 150 · cited 1×
“Whether the observed defects in NOx metabolism are due to diabetes itself, to the accompanying nephropathy, or to insulin-resistance, possibly amplified by hypertension (35), cannot be concluded from our experiments.”
The Renin-Angiotensin System and Diabetic Nephropathy
Gurley, S. B., & Coffman, T. M. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.01.009 · Cited by 144 · cited 1×
“Hypertension however is an invariable finding in T2DM with nephropathy (36), therefore it would be impossible to distinguish between the effects of diabetes per se from those of hypertension in these patients.”
Increased basal levels of plasma nitric oxide in Type 2 diabetic subjects
Maejima, K., Nakano, S., Himeno, M., Tsuda, S.-I., Makiishi, H., Ito, T., Nakagawa, A., Kigoshi, T., Ishibashi, T., Nishio, M., et al. (2001) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(01)00144-1 · Cited by 142 · cited 1×
“Syndrome (17-18), thus questioning the validity of urinary methods to assess whole-body NOx production.”
Workshop: Endothelial Cell Dysfunction Leading to Diabetic Nephropathy: Focus on Nitric Oxide
Goligorsky, M. S., Chen, J., & Brodsky, S. (2001) · Hypertension · doi:10.1161/01.hyp.37.2.744 · Cited by 140 · cited 3×
“Moreover, high glucose and/or the associated advanced glycosylation end products decreased NOS expression (11).”
BackgroundInfluentialKashyap, S. R., Roman, L. J., Lamont, J., Masters, B. S. S., Bajaj, M., Suraamornkul, S., Belfort, R., Berria, R., Kellogg, D. L., Liu, Y., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0745 · Cited by 139 · cited 3×
“Indeed, basal and insulinstimulated muscle NOS activity was impaired in well-controlled type 2 diabetic subjects, paralleling the severity of insulin resistance (19).”
InfluentialJungersten, L., Edlund, A., Petersson, A., & Wennmalm, Å. (1996) · Clinical Physiology · doi:10.1111/j.1475-097x.1996.tb00726.x · Cited by 134 · cited 1×
“The absolute synthesis rate of NOx (ASR) (in mmol per day) is then calculated by multiplying FSR times the total NOx pool, which is the product between the average whole-blood NOx concentration (in mmol/l) of each experimental period and the nitrate distribution volume (in liters), taken as 28% of body weight (26).”
Andreozzi, F., Laratta, E., Procopio, M. C., Hribal, M. L., Sciacqua, A., Perticone, M., Miele, C., Perticone, F., & Sesti, G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01340-06 · Cited by 123
Satoh, M., Fujimoto, S., Arakawa, S., Yada, T., Namikoshi, T., Haruna, Y., Horike, H., Sasaki, T., & Kashihara, N. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn357 · Cited by 106 · cited 1×
“These drugs may affect NOS activity (31-34).”
Zhou, M.-S., Schulman, I. H., Jaimes, E. A., & Raij, L. R. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00041.2008 · Cited by 106
Serum nitric oxide metabolites in subjects with metabolic syndrome
Zahediasl, S., Ghasemi, A., & Azizi, F. (2008) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2008.08.076 · Cited by 103
Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus
Hamilton, S. J., Chew, G. T., & Watts, G. F. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.026 · Cited by 94 · cited 1×
“These drugs may affect NOS activity (31-34).”
l-Arginine-Nitric Oxide Kinetics in Normal and Type 2 Diabetic Subjects
Avogaro, A., Toffolo, G., Kiwanuka, E., de Kreutzenberg, S. V., Tessari, P., & Cobelli, C. (2003) · Diabetes · doi:10.2337/diabetes.52.3.795 · Cited by 64
Self-citationHigh concentration of glucose inhibits glomerular endothelial eNOS through a PKC mechanism
Chu, S., & Bohlen, H. G. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00006.2004 · Cited by 60 · cited 2×
“On the other hand, since high glucose inhibits NOS activity per se (15), the acute insulin-induced glucose decrease was not responsible for the blunted increased of NO production observed in the patients.”
Vanizor, B., Örem, A., Karahan, S. C., Kiran, E., Erem, C., Aliyazıcıoğlu, R., & Uydu, H. A. (2001) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(01)00281-9 · Cited by 47 · cited 7×
“T2DM, type 2 diabetic subjects.”
InfluentialEarle, K., Mehrotra, S., Dalton, R. N., Denver, E., & Swaminathan, R. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v12102125 · Cited by 40
The Role of Inflammation in Vascular Insulin Resistance with Focus on IL-6
Andersen, K., & Pedersen, B. (2008) · Hormone and Metabolic Research · doi:10.1055/s-0028-1083810 · Cited by 37
New functional aspects of the L-arginine-nitric oxide metabolism within the circulating blood
Keymel, S., Kelm, M., & Kleinbongard, P. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-04-0305 · Cited by 37 · cited 1×
“3 itric oxide is a key regulatory molecule with extensive metabolic, vascular and cellular effects (1-6).”
Acute effect of insulin on nitric oxide synthesis in humans: a precursor-product isotopic study
Tessari, P., Coracina, A., Puricelli, L., Vettore, M., Cosma, A., Millioni, R., Cecchet, D., Avogaro, A., Tiengo, A., & Kiwanuka, E. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00481.2006 · Cited by 22 · cited 6×
“Thereafter, an euglycemic, hyperinsulinemic clamp was started as described elsewhere (20).”
InfluentialSelf-citation
Cited by
Targeting epigenetic mechanisms in diabetic wound healing
den Dekker, A., Davis, F. M., Kunkel, S. L., & Gallagher, K. A. (2019) · Translational Research · doi:10.1016/j.trsl.2018.10.001 · Cited by 235
“Sustained high glucose and insulin-resistance causes platelets to release high levels of fibrinogen and plas- minogen activator inhibitor 1 (PAI-1) making them more adherent to the vascular endothelium and are more likely to aggregate.46,47 Additionally, under dia- betic conditions, platelets have been shown to be les…”
Adam, J., Brandmaier, S., Leonhardt, J., Scheerer, M. F., Mohney, R. P., Xu, T., Bi, J., Rotter, M., Troll, M., Chi, S., et al. (2016) · Diabetes · doi:10.2337/db16-0512 · Cited by 68
“This underlies the clinical practice guidelines, which have recommended the use of metformin as first-line therapy in T2D patients with cardiovascular disease, mainly in patients with observed reduced NO levels (45).”
MethodPhosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy
Scheele, W., Diamond, S., Gale, J., Clerin, V., Tamimi, N., Le, V., Walley, R., Grover-Páez, F., Perros-Huguet, C., Rolph, T., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015050473 · Cited by 65
Vitamin C supplementation for diabetes management: A comprehensive narrative review
Mason, S. A., Parker, L., van der Pligt, P., & Wadley, G. D. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.12.003 · Cited by 53
Siervo, M., Stephan, B. C. M., Feelisch, M., & Bluck, L. J. C. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.05.032 · Cited by 52
“Flow chart describing the results of the search strate logical states [49,50,52,60,67,71], or procedures likely to affect NO production or had carried out repeated measurements of NO production using a before-and-after measurement protocol [39,46,48,51,54,64,70].”
BackgroundMethodResultInfluential
Metadata
- Authors
- Tessari, P., Cecchet, D., Cosma, A., Vettore, M., Coracina, A., Millioni, R., Iori, E., Puricelli, L., Avogaro, A., & Vedovato, M.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-05-18
- Volume
- 59
- Issue
- 9
- Pages
- 2152-2159
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2170109807
- Cited by
- 186
- References
- 42
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.